Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
HRMY 
Harmony Biosciences Holdings (HRMY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: HRMY (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $45.91
1 Year Target Price $45.91
| 5 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.29% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.18B USD | Price to earnings Ratio 11.95 | 1Y Target Price 45.91 |
Price to earnings Ratio 11.95 | 1Y Target Price 45.91 | ||
Volume (30-day avg) 9 | Beta 0.84 | 52 Weeks Range 25.52 - 40.93 | Updated Date 01/9/2026 |
52 Weeks Range 25.52 - 40.93 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.17 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 22.48% | Operating Margin (TTM) 27.35% |
Management Effectiveness
Return on Assets (TTM) 13.2% | Return on Equity (TTM) 25.93% |
Valuation
Trailing PE 11.95 | Forward PE 8.5 | Enterprise Value 1677099077 | Price to Sales(TTM) 2.64 |
Enterprise Value 1677099077 | Price to Sales(TTM) 2.64 | ||
Enterprise Value to Revenue 2.03 | Enterprise Value to EBITDA 6.22 | Shares Outstanding 57596358 | Shares Floating 50705530 |
Shares Outstanding 57596358 | Shares Floating 50705530 | ||
Percent Insiders 12.14 | Percent Institutions 88.59 |
Upturn AI SWOT
Harmony Biosciences Holdings
Company Overview
History and Background
Harmony Biosciences Holdings, Inc. was founded in 2017. It is a biopharmaceutical company focused on developing and commercializing treatments for rare neurological disorders. A significant milestone was the FDA approval of its first drug, WAKIXu00ae, in 2019 for the treatment of narcolepsy. The company has since expanded its focus to include other conditions related to hypocretin deficiency.
Core Business Areas
- Neurological Disorder Treatments: Development and commercialization of therapies for rare neurological disorders, primarily focusing on conditions related to hypocretin deficiency, such as narcolepsy.
Leadership and Structure
Harmony Biosciences is led by a management team with experience in the biopharmaceutical industry. The organizational structure is typical for a commercial-stage biopharmaceutical company, with dedicated departments for research and development, commercial operations, medical affairs, and corporate functions.
Top Products and Market Share
Key Offerings
- Competitors: Modafinil (Provigil),Armodafinil (Nuvigil),Sodium Oxybate (Xyrem, Xywav)
- Market Share Data:
- Number of Users:
- Product Name 1: WAKIXu00ae (pitolisant). WAKIXu00ae is the first and only FDA-approved medication indicated for the treatment of excessive daytime sleepiness (EDS) and cataplexy in patients 6 years of age and older with narcolepsy. It is a first-in-class histamine H3 receptor antagonist/inverse agonist. Competitors in the narcolepsy market include drugs for symptom management, although WAKIXu00ae offers a unique mechanism of action. Market share data for specific drugs within rare disease indications can be proprietary and difficult to ascertain publicly. However, WAKIXu00ae has established itself as a leading therapy for narcolepsy.
- Revenue from Product:
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the rare disease segment, is characterized by high unmet medical needs, significant R&D investment, and a focus on specialized therapies. Companies in this space often benefit from regulatory incentives such as orphan drug designations, which can provide market exclusivity.
Positioning
Harmony Biosciences is positioned as a leader in the treatment of narcolepsy, with a unique mechanism of action. Its focus on rare neurological disorders with high unmet needs provides a distinct market niche.
Total Addressable Market (TAM)
The total addressable market for narcolepsy treatments is estimated to be in the hundreds of millions to low billions of dollars globally. Harmony Biosciences, through its flagship product WAKIXu00ae, is addressing a significant portion of this market, particularly for patients with EDS and cataplexy. The company is also exploring opportunities in other related rare conditions, which could further expand its TAM.
Upturn SWOT Analysis
Strengths
- First-in-class therapy for narcolepsy with a unique mechanism of action (WAKIXu00ae).
- Strong focus on rare neurological disorders with significant unmet medical needs.
- Experienced leadership team with a proven track record in the biopharmaceutical sector.
- Orphan drug designation and potential for market exclusivity for WAKIXu00ae.
Weaknesses
- Limited product portfolio, heavily reliant on the success of WAKIXu00ae.
- The relatively small patient population for rare diseases can limit broad market penetration.
- Ongoing R&D costs associated with developing new therapies.
Opportunities
- Expansion of WAKIXu00ae indications to other hypocretin deficiency disorders.
- Development of new drug candidates for other rare neurological conditions.
- Geographic expansion for WAKIXu00ae and future products.
- Potential for strategic partnerships or acquisitions to broaden the pipeline.
Threats
- Competition from existing or new therapies for narcolepsy and related disorders.
- Regulatory hurdles and potential delays in drug approvals.
- Pricing pressures and reimbursement challenges.
- Patent expirations and the emergence of generics for other narcolepsy treatments.
Competitors and Market Share
Key Competitors
- Jazz Pharmaceuticals (JAZZ)
- Sumitomo Pharma Co., Ltd. (based in Japan, with US operations)
Competitive Landscape
Harmony Biosciences's competitive advantage lies in its first-in-class therapy for narcolepsy with a differentiated mechanism. Competitors like Jazz Pharmaceuticals also have significant products in the sleep disorder space, requiring Harmony to maintain strong marketing and clinical differentiation. The market is characterized by high barriers to entry due to R&D costs and regulatory complexity.
Growth Trajectory and Initiatives
Historical Growth: Harmony Biosciences has experienced substantial revenue growth since the launch of WAKIXu00ae. The company's focus on a niche but important therapeutic area has allowed for rapid market penetration.
Future Projections: Analyst projections for Harmony Biosciences indicate continued revenue growth, driven by increasing adoption of WAKIXu00ae and potential expansion into new indications or markets. Profitability is also projected to improve as the company scales its operations.
Recent Initiatives: Recent initiatives likely include expanding the commercial team for WAKIXu00ae, investing in further clinical trials to support label expansion, and potentially exploring new therapeutic targets within rare neurological disorders.
Summary
Harmony Biosciences Holdings is a strong player in the rare neurological disorder space, particularly for narcolepsy, with its innovative drug WAKIXu00ae. The company has demonstrated impressive revenue growth and has significant opportunities for expansion. Key areas to watch include ongoing clinical trials for new indications, competitive pressures, and the company's ability to maintain its market leadership through continued innovation and effective commercialization.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Harmony Biosciences Holdings Investor Relations
- SEC Filings (10-K, 10-Q)
- Industry Analysis Reports
- Financial Data Providers (e.g., Refinitiv, Bloomberg - simulated for this response)
Disclaimers:
This JSON output is generated based on publicly available information and simulated financial data for illustrative purposes. It is not financial advice. Investors should conduct their own due diligence before making any investment decisions. Market share data and TAM are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Harmony Biosciences Holdings
Exchange NASDAQ | Headquaters Plymouth Meeting, PA, United States | ||
IPO Launch date 2020-08-19 | President, CEO & Director Dr. Jeffrey M. Dayno M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 268 | |
Full time employees 268 | |||
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.